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Abstract
Background: Zoonotic visceral leishmaniasis (VL) is a severe infectious disease caused by protozoan parasites of the genus
Leishmania and the domestic dogs are the main urban parasite reservoir hosts. In Brazil, indirect fluorescence antibody tests
(IFAT) and indirect enzyme linked immunosorbent assay (ELISA) using promastigote extracts are widely used in
epidemiological surveys. However, their sensitivity and specificity have often been compromised by the use of complex
mixtures of antigens, which reduces their accuracy allowing the maintenance of infected animals that favors transmission to
humans. In this context, the use of combinations of defined peptides appears favorable. Therefore, they were tested by
combinations of five peptides derived from the previously described Leishmania diagnostic antigens A2, NH, LACK and K39.
Methodology/Principal Findings: Combinations of peptides derived A2, NH, LACK and K39 antigens were used in ELISA
with sera from 44 human patients and 106 dogs. Improved sensitivities and specificities, close to 100%, were obtained for
both sera of patients and dogs. Moreover, high sensitivity and specificity were observed even for canine sera presenting low
IFAT anti-Leishmania antibody titers or from asymptomatic animals.
Conclusions/Significance: The use of combinations of B cell predicted synthetic peptides derived from antigens A2, NH,
LACK and K39 may provide an alternative for improved sensitivities and specificities for immunodiagnostic assays of VL.
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Introduction
Zoonotic visceral leishmaniasis (VL) caused by Leishmania
infantum is an important emerging parasitic disease found in
countries around the Mediterranean basin, in the Middle East,
and in Latin America [1,2]. In these areas, wild canids constitute
major sylvatic reservoirs, and domestic dogs are the principal
urban reservoir hosts [3,4]. Hence, euthanasia of seropositive dogs
has been adopted as a mainstay control measure in some countries
[5]. However, domestic reservoir control programs may fail
because of the high incidence of canine infection, the insensitivity
of the diagnostic tests to detect infectious dogs and time delays
between diagnosis and euthanasia by public health services [4].
Although adopted in European countries, treatment of infected
dogs is not allowed in Brazil, based on the assumption that treated
dogs may also remain as a source of parasites for sand fly infection.
In this context, sensitive diagnostic tests, applicable to field
conditions, are becoming increasingly necessary to facilitate and
improve the control of disease [6].
Enzyme-linked immunosorbent assays (ELISAs) [7] and indirect
fluorescence antibody tests (IFAT) [8] are widely used for
serological diagnosis of VL. However, these tests present relative
low sensitivity and specificity, which underestimates the actual rate
of infection and allows the maintenance of infected animals and
transmission. Several defined Leishmania antigens have been tested
to overcome these difficulties and to improve both sensitivity and
specificity [9]. Immunochromatographic tests for the diagnosis of
leishmaniasis using the rK39 antigen has been evaluated in several
countries, with variable results [6,10,11]. Development of effective
diagnosis is also critical for control and possible eradication of
visceral leishmaniasis and sensitive and specific rapid tests may be
especially helpful to achieve this goal [12]. Therefore, there are
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including identification and combination antigens and test
formats.
B cell epitopes prediction by bioinformatics analysis of protein
sequences has been proposed as a good alternative to select
peptides for diagnostic tests [13,14]. In the present study, we
tested, in ELISA against sera from 44 patients and 106 dogs,
combinations of predicted B cell peptides derived from A2, NH,
LACK and K39, which have been previously evaluated as
antigens for serodiagnosis of visceral leishmaniasis [15–21].
Improved sensitivity for detection of asymptomatic and symptom-
atic canine visceral leishmaniasis (CVL), including canine sera
with low anti-Leishmania antibody titers as detected by IFAT, and
active disease in human patients was demonstrated for the
majority of the peptide combinations.
Methods
Ethics Statement
Sera of dogs were obtained from already-existing collections
(Sera collection of the Laboratory of Molecular Biology of the
Faculty of Pharmacy, Federal University of Minas Gerais).
Approval to use the samples was obtained from institutional
review board (IRB) - Comite ˆd eE ´tica em Experimentac ¸a ˜o Animal
(CETEA) from Universidade Federal de Minas Gerais (UFMG),
under the protocol 20/2010.
Sera of human patients were also obtained from an already-
existing collection (Sera collection of the Laboratory of Immuno-
parasitology of the Research Center Rene ´ Rachou, Fundac ¸a ˜o
Oswaldo Cruz). IRB approval to use the samples was obtained
from the Institutional Committee on Ethics of Human Research of
Fundac ¸a ˜o Oswaldo Cruz, under the protocol 12/2006. All
samples were analyzed anonymously.
Mapping B-cell Epitopes
The aminoacid sequence of A2 (amastigote stage-specific S
antigen homolog of L. donovani), k39 (kinesin related protein of L.
chagasi), LACK (Leishmania analogue of the receptor kinase C) and
NH (nucleoside hydrolase) proteins were subjected to analysis with
software available online at http://www.expasy.org/tools/
protscale.html. The analyses generate numerical and graphical
scores to predict the position of linear B-cell epitopes. Peptides that
fulfilled, at least in part, the criteria of high hydrophilicity (Hoop
&Woods), high alpha-helix structures (Chou & Fasman), low coil
(Deleage & Roux), low beta-sheet structures (Chou & Fasman),
high percentage of accessible residues and low beta-turn structures
(Chou & Fasman) were selected for synthesis and screening. The
selected peptides were also submitted to BepiPred software
(http://www.cbs.dtu.dk/services/BepiPred/) to predict the loca-
tion of linear B-cell epitopes using a combination of a hidden
Markov model and a propensity scale method [13]. BepiPred
software scores peptides according to hydrophilicity values,
secondary structures and the probability of a aminoacid is located
in certain positions as compared to other mapped B cell epitopes.
Peptides displaying scores higher than 0.35 may be, therefore,
considered putative B cell epitopes.
Synthetic peptides
Peptides were synthesized according to a standard N-9-
ethyloxycarbonyl (Fmoc) strategy on a PSSM8 multispecific
peptide synthesizer (Shimadzu, Kyoto, Japan) by solid-phase
synthesis and were purified by high performance liquid chroma-
tography and confirmed with a Micromass Q-Tof Micro
(Micromass MS Technologies, Division of Waters, Milford, MA)
and the peptides obtained by this method were all C-terminal
amides.
Dog sera and infection status
A panel of 106 canine sera was used in the study. Serum
samples were divided into threeg r o u p sb a s e do nh i s t o r yo f
exposure and infection status. Group 1 contained negative
control sera from 14 healthy blood donor pets of various ages
and breeds (previously classified as seronegative dogs after
ELISA-based assays for the detection of antibodies against
parasite-specific recombinant antigens rK39, rK26, and rA2)
that attended a veterinary clinic in Minas Gerais, Brazil. Group
2 contained 30 serum samples from clinically symptomatic
(n=17) and asymptomatic (n=13) dogs in which L. infantum
visceral infection was proven by the demonstration of the
presence of the parasites in bone marrow specimens and/or
necropsy tissue samples as previously reported [21]. All infected
dogs enrolled in this group were selected during a longitudinal
epidemiological survey of CVL carried out in a rural area of
endemicity (Pancas, ES; 2003–2004) in southeast Brazil [22].
Group 3 contained sera from 62 dogs with L. infantum infection
from CVL endemic areas in Brazil. They had been previously
tested in IFAT and ELISA. Serap r e s e n t i n gI F A Tt i t e r s.1:40
dilutions and ELISA optical densities.cut off values (cut off
values were determined by the mean of OD of 14 negative
canine control sera plus two standard deviations) were consid-
e r e dp o s i t i v e( I g G )f o rC V L .A l l6 2s a m p l e sh a dt h e i rs t a t u s
confirmed by parasitological analyses which included the search
for parasites in bone marrow aspirates by PCR, microscopic
examination of Giemsa stained smears and culturing in NNN/
LIT medium at 23uC, as previously described [23]. Since a
significant correlation was observed between IFAT and ELISA
tests for all sera samples (data not shown), positive sera in group
3 were further grouped, according to their previous reactivity in
IFAT, regardless its clinical status, as low (n=20) (,1:320
dilutions), intermediate (n=20) (.1:320 ,1:640) and high
(n=22)(.1:640) IFAT titers.
Author Summary
Visceral leishmaniasis is endemic in many areas of tropical
and subtropical America where it constitutes a significant
public health problem. It is usually diagnosed by enzyme-
linked immunosorbent assays (ELISA) using crude Leish-
mania antigens, but a variety of other immunological
methods may also be applied. Although these approaches
are useful, historically their sensitivity and specificity have
often been compromised by the use of complex mixtures
of antigens. In this context, the use of combinations of
purified, well-characterized antigens appears preferable
and may yield better results. In the present study,
combinations of peptides derived from the previously
described Leishmania diagnostic antigens A2, NH, LACK
and K39 were used in ELISA against sera from 106 dogs
and 44 human patients. Improved sensitivities and
specificities, close to 100%, for both sera of patients and
dogs was observed for ELISA using some combinations of
the peptides, including the detection of VL in dogs with
low anti-Leishmania antibody titers and asymptomatic
infection. So, the use of combinations of B cell predicted
synthetic peptides derived from antigens A2, NH, LACK
and K39 may provide an alternative for improved
sensitivities and specificities for immunodiagnostic assays
of VL.
Peptides for Immunodiagnosis of Leishmaniasis
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H u m a nV Ls e r aw e r eo b t a i n e df r o mp a t i e n t sw i t ha c t i v e
visceral leishmaniasis (n=28). Diagnosis of VL was defined when,
besides clinical and epidemiologic features, amastigotes were seen
at Giemsa stained smears of bone marrow aspirates or
promastigote forms were identified on culture of peripheral
blood or bone marrow aspirates. In the presence of suggestive
clinical and epidemiologic characteristics, negative parasitological
findings, but positive anti-Leishmania antibodies by IFAT or
ELISA, definitive diagnostic was firmed after successful specific
treatment. Control sera (n=16) were obtained from individuals
living in Vale do Jequitinhonha (in cities: Sa ˜o Pedro do
Jequitinhonha, Caju, Virgem das Grac ¸as e Melquı ´ades), a rural
region of Minas Gerais State in southeast Brazil. None of the
individuals presented signs of visceral leishmaniasis at clinical
examination. All of them had negative results for specific
Leishmania PCR in sera samples. Sera samples were also submitted
to ELISA with the crude extract of the parasite to confirm that
they were negative.
Enzyme-linked immunosorbent assays ELISA for canine
sera
Levels of total IgG immunoglobulin were measured by ELISA.
Briefly, 96-well flexible PVC plates (BD Biosciences, San Jose, CA)
were sensitized with 5 mg/mL of each synthetic peptide diluted in
water (100 mL per well). The sensitized plate was left in the oven
until dry and then was left overnight at 4uC. Plates were blocked
with PBS-2% casein at 37uC for 1 h and treated successively with
1:200 dilutions of canine serum samples for 1 h at 37uC.
Peroxidase labeled antibodies specific to canine IgG (Sigma, St.
Louis, MO) were diluted at 1:5000 and added for 1 h at 37uC.
Following another washing step, the enzyme bound to the
immunosorbent is assayed by the addition of a chromogenic
substrate, 3,39,5,59-tetramethylbenzidine (TMB) in citrate buffer
containing hydrogen peroxide. Reactions were stopped by the
addition of H2SO4 2N. Optical densities were determined at
450 nm in ELISA reader (BioRad, Hercules, CA). Each sera
sample was assayed in triplicate. The lower limit of positivity (cut
off) was determined by the mean of OD of 14 negative canine
control sera plus two standard deviations.
Enzyme-linked immunosorbent assays ELISA for human
sera
Sensitization of the plates followed the same as described above.
However, plates were sensitized with 40 mg/mL of each synthetic
peptide diluted in water (100 mL per well, resulting in 4 mg/well).
When 2 peptides were tested simultaneously (peptides 13 and 47,
13 and 19, 18 and 19, 17 and 47 and 19 and 47), plates were
sensitized with 20 mg/mL of each synthetic peptide. After antigen
sensitization, the plates were blocked with 2% BSA at 37uC for 2 h
and treated successively with 1:100 dilutions of patients serum
samples for 1 h at 37uC. After washing step, biotinilated labeled
antibodies human-IgG (Sigma, St. Louis, MO) were diluted at
1:5000 and added to the plate for 1 h at 37uC. Then, add the
streptavidin-peroxidase conjugate diluted 1:1000 for 30 minutes at
37uC. After three washes, the substrate 3,39,5,59-tetramethylben-
zidine (TMB) in citrate buffer containing hydrogen peroxide were
added to the plate. Reactions were stopped by the addition of
H2SO4 2N. Optical densities were read at 450 nm in ELISA
reader (BioRad, Hercules, CA). Each sera sample was assayed in
triplicate. The lower limit of positivity (cut off) was determined by
the mean of OD of 16 negative human control sera plus two
standard deviations.
Statistical analysis
One-Way ANOVA test was used to compare the performances
of the assays. A p value of less than 0.05 was considered significant.
Sensitivity and specificity were calculated by binary classification
test. The sensitivity and specificity for each test were calculated by
using the formulas: Sensitivity=True positive/(True positive+
False negative)6100% and Specificity=True negative/(True
negative+False positive)6100%.
Results
Bioinformatics analysis
The study of the structure of proteins (ProtScale) allowed the
selection of five peptides, as shown in Table 1: TPAVQKRV-
KEVGTKP and TTVVGNQTLEKVT, corresponding to num-
bers 17 and 18 peptides, respectively, derived from Nucleoside
Hydrolase antigen, VVSTSRDGTAISWK, corresponding to
peptide 19, derived from LACK protein and ESTTAAKMSAEQ-
DRESTRATLE, corresponding to peptide number 13, derived
from K39 protein. Additionally, in Table 1 is represented the
peptide derived from the A2 protein, corresponding to peptide 47
(VGPQSVGPLSVGPQSVGPLS). However, the inclusion of this
peptide was based on previous analysis of epitope prediction and
reactivity with sera of BALB/c mice vaccinated with the A2
antigen [24]. Among the peptides select, 4 (peptides 13, 17, 19 and
47) also showed linear B-cell epitopes with significant values in the
analysis by BepiPred, with emphasis on peptides 13 and 47,
derived from K39 and A2 antigens, which presented higher scores.
By contrast, the peptide 18 showed a low score for the presence of
linear B-cell epitopes.
Reactivity of dogs and human visceral leishmaniasis sera
with the selected peptides
Initially, to test the reactivity of the selected peptides with
antibodies present in dogs’ sera with VL, the spot synthesis
technique, followed by immunoassay was applied (data not
shown). The membranes were incubated with a pool of sera from
infected and control animals. Four of the five peptides showed
high intensity reactions with sera of dogs with confirmed VL as
compared with the control group. Peptide 19 presented reactivity
with both positive and negative sera. However, considering the use
of pooled sera on the spot synthesis experiment, peptide 19 was
also included in a more discriminatory analysis through ELISA
with individual sera samples.
All peptides were then tested against Group 2 sera, which
included samples collected from symptomatic and asymptomatic
animals (Figure 1). As shown in figure 1, all peptides were able to
detect as positives all the sera samples from both asymptomatic
(n=13) and symptomatic animals (n=17) Figure 1. No significant
differences were observed in sensitivity between the two groups.
The reactivity of the 5 peptides was further evaluated with a
larger panel of sera from parasitological positive (Group 3) or
control dogs (Group 1), which included sera samples classified
according to IFAT reactivity as low (,1:320 dilutions), interme-
diate (.1:320 ,1:640) and high (.1:640) titers (Figure 2). High
sensitivity (100%) was observed for all peptides to detect infection
in dogs with high IFAT antibody titers (22 animals), when the
peptides were tested individually (Figure 2/Table 2). However,
decreased sensitivities (varying between 55% and 90%) were
observed for all peptides when tested against sera of dogs with
IFAT intermediate (.1:320 ,1:640) (20 animals) or low antibody
titers (1:80 .1:320) (20 animals) (Table 2). Concerning specificity,
a value of 100% was observed for peptide 17 and 92% for the
other peptides, as shown in Table 2.
Peptides for Immunodiagnosis of Leishmaniasis
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individually with sera of dogs with intermediate and low IFAT
titers, we tested the hypothesis that the sensitivity to detect VL
would increase by combining peptides in the same reaction.
Assuming this would increase sensitivity by broaden instead of
simply increasing the number of available epitopes for reaction,
half of the concentration was used for each peptide instead of
double the total peptide concentration. Combinations of two
peptides were then tested against dog sera with low and
intermediate antibody titers (Figure 3/Table 2). For sera with
low antibody titers, the best results, i.e, improved sensitivities as
compared to peptides tested individually, ranged from 90% to
95%, were obtained with combinations between the peptides 13
and 47, 13 and 19, 18 and 19, 47 and 17 and 47 and 18.
Specificity was also improved, reaching 100% for all of these
combinations. The sensitivity of peptide 47 was not altered when
combined with peptide 17, which in contrast, had its sensitivity
improved from 85% to 90% (Figure 3/Table 2). For sera with
intermediate antibody titers, improved sensitivities for both
peptides were observed for combinations between peptides 13
Table 1. Bioinformatic analysis of A2, K39, LACK and NH proteins to predict linear B-cell epitopes.
ExPASy Parameters Peptide 13 Ppetide 17 Peptide 18 Peptide 19 Peptide 47
Av (Max;Min)/Prot Alpha-helix 1.1 (0.6; 1.3) 1 (0.7; 1.2) 0.96 (0.7; 1.2) 0.88 (0.7; 1.2) 0.77 (0.7; 1.2)
Beta-turn 0.9 (0.6; 1.3) 0.83 (0.6; 1.3) 0.9 (0.6; 1.3) 0.91 (0.7; 1.3) 1.13 (0.6; 1.2)
Beta-sheet 0.85 (0.6; 1.2) 1.1 (0.8; 1.3) 1.1 (0.8; 1.3) 1 (0.7; 21.3) 1 (0.7; 1.4)
Coil 0.95 (0.8; 1.1) 1 (0.8; 1.2) 0.93 (0.8; 1.2) 0.92 (0.8; 21.1) 1.13 (0.8; 1.15)
% Ac. residues 6.6 (4.2; 8) 6.4 (4; 7) 6.2 (4; 7) 5.8 (3.6; 7.4) 6.08 (4.2; 7)
Hydrophilicity 0.73 (21.2; 2) 0.6 (21.2; 1.3) 20.1 (21.2; 1.3) 0.12 (21; 1.2) 20.4 (21.4; 0.6)
BepiPred Parameters Peptide 13 Ppetide 17 Peptide 18 Peptide 19 Peptide 47
Max; Min/aa Score.0.35 0.12; 1.53 0.33; 1.33 0.03; 0.51 0.01; 1.08 0.69; 1.64
Av: Average, Max: Maximum, Min: Minimum, Prot: Protein, aa: Aminoacid, Ac: Acid.
doi:10.1371/journal.pntd.0001622.t001
Figure 1. ELISA with individual synthetic peptides for detection of IgG-antibodies in dogs with L. infantum infection. Detection of anti-
leishmanial total IgG antibodies with synthetic peptides by ELISA assay using sera from asymptomatic (n=13) and symptomatic (n=17) dogs and
control group (n=14). It was used 500 nanograms/well of peptides 13 (panel A), 17 (panel B), 18 (panel C), 19 (panel D) and 47 (panel E). The
sensitivity and specificity of asymptomatic and symptomatic dogs ranged between 100 and 90%, respectively, for both.
doi:10.1371/journal.pntd.0001622.g001
Peptides for Immunodiagnosis of Leishmaniasis
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sensitivity of peptide 47 (85%) was not affected when combined
with peptide 13 and decreased when associated to peptide 17
(Figure 3/Table 2).
Peptides were also tested (individually and combined) against
human sera (n=44) including patients with active visceral
leishmaniasis (n=28) and healthy individuals with previous
negative results in ELISA to Leishmania (n=16). The results
obtained are shown in Figure 4 and 5/Table 3. Sensitivity values
of 82%, 93% and 96% were observed for peptides 18, 47 and 13,
respectively. And ELISA with peptides 17 and 19 gave the best
results, displaying sensitivities of 100%. The specificity for the
peptides tested individually ranged from 81% to 94%. The
combination of peptides brought an improvement in sensitivity
Figure 2. Reactivity of sera from infected dogs displaying different IFAT antibody titers with peptides. Detection of anti-leishmanial
total IgG antibodies with synthetic peptides by ELISA assay using canine samples classified according to IFAT reactivity as low (,1:320 dilutions),
intermediate (.1:320 ,1:640) and high (.1:640) titers and 500 nanograms/per well of peptides 13 (panel A), 17 (panel B), 18 (panel C), 19 (panel D)
and 47 (panel E).
doi:10.1371/journal.pntd.0001622.g002
Table 2. Performance of ELISA employing synthetic peptides and canine sera classified according to IFAT reactivity.
Peptides Low Titer* (n=20) Intermediate Titer (n=20) High Titer (n=22) Uninfected Dogs (n=14)
Se (%) Se (%) Se (%) Sp (%)
13 85 75 100 92
17 85 75 100 100
18 70 55 100 92
19 90 85 100 92
47 90 85 100 92
13 and 47 95 85 ND 100
13 and 19 95 95 ND 100
18 and 19 95 90 ND 100
47 and 17 90 80 ND 100
47 and 18 95 95 ND 100
Se: sensitivity, Sp: specificity.
*canine sera samples were classified according to IFAT reactivity as low (,1:320 dilutions) and intermediate (.1:320 ,1:640) titers and high (.1:640) antibody titers.
doi:10.1371/journal.pntd.0001622.t002
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and 19 and 47 where we observe a sensitivity of 100% for the first
three combinations and 95.65% for the last one, respectively. Only
for the combination between peptides 17 and 47 a reduction in
sensitivity to 70.83% was observed. Specificity values for all
combination ranged from 93.10% to 100% (Figure 4 and 5/
Table 3).
Discussion
In the present work, the Leishmania proteins A2, K39, LACK
and NH were submitted to B cell epitope prediction and the
derived synthetic peptides were evaluated through ELISA
against sera of dogs and patients for the serodiagnosis of VL.
Using the Protscale software, six different parameters were
evaluated for each protein to select peptides. Considering the
scores for these parameters, an adequate profile was observed for
the majority of peptides, as compared to the minimal and
maximum scores for the corresponding proteins, except for
peptide 47. Peptide 47 displayed the lower values for hydrophi-
licity and presence of alpha helix, which are expected to be high
for B cell epitopes, and the highest values for coil and beta turn
structures, which in contrast are expected to be low. On the
other hand, prediction using BepiPred resulted in scores higher
than 0.35 for all peptides, except for peptide 18. Altogether, our
results indicate that the two analyses may be complementary to
each other and that this strategy is useful for selecting diagnostic
antigens.
Accurate diagnosis of canine leishmaniasis is essential towards a
more efficient control of this zoonosis, but it remains problematic
due to the high incidence of asymptomatic infections [25].
Initially, we tested the five peptides with sera from dogs clinically
classified as asymptomatic and symptomatic (Group 2). It is
noteworthy that the sera samples of Group 2 have been previously
tested in ELISA using SLA or the recombinant proteins rA2, rK39
and rK26 [21]. The retrospective analysis of the data obtained by
Porrozzi et al. (2007) revealed that 4, 9, 5 and 4 out of 13 sera from
asymptomatic animals included in the present study, were not
reactive with SLA, rA2, rK39 and rK26, respectively, whereas all
the symptomatic samples were positive when either rK26, rK39 or
SLA were used as antigens. Using rA2, 6 symptomatic sera
samples were identified as negative. Moreover, the majority of
samples that were not reactive with these antigens were obtained
from asymptomatic animals presenting low antibody titers in IFAT
(#1:80). In the present analysis, for both asymptomatic and
symptomatic VL canine sera, sensitivities and specificities of 90%
and 100%, respectively, were observed. Therefore, improved
sensitivity was observed for assays using the synthetic peptides as
compared to SLA and the recombinant proteins, especially for
sera of asymptomatic animals. In this sense, our results largely
confirm and improve the potential of these antigens for
serodiagnosis of leishmaniasis.
Detection of infection in animals with low or intermediated anti-
Leishmania antibody titers, regardless their clinical status, is critical
for diagnosis and control of VL. The failure to detect infection in
these animals may contribute to the maintenance of parasite’s
Figure 3. Reactivity of sera from infected dogs displaying different antibody titers with combined peptides. Detection of anti-
leishmania total IgG antibodies with synthetic peptides by ELISA assay using canine samples classified according to IFAT reactivity as low (,1:320
dilutions) and intermediate (.1:320 ,1:640) titers and 250 nanograms/per well from each peptide. Peptides were combined in pairs in the same
reaction as following: peptides 13 and 47 (panel A), 13 and 19 (panel B), 18 and 19 (panel C), 47 and 17 (panel D) and 47 and 18 (panel E).
doi:10.1371/journal.pntd.0001622.g003
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www.plosntds.org 6 May 2012 | Volume 6 | Issue 5 | e1622Figure 4. Detection of IgG-antibodies in sera of human patients with visceral leishmaniasis with individual peptides. Detection of
anti-leishmania total IgG antibodies with synthetic peptides by ELISA assay using sera from patients with active visceral leishmaniasis (n=28) and
healthy individuals with previous negative results in ELISA to Leishmania (n=16) and 4 mg/per well peptides 13 (panel A), 17 (panel B), 18 (panel C),
19 (panel D) and 47 (panel E).
doi:10.1371/journal.pntd.0001622.g004
Figure 5. Detection of IgG-antibodies in sera of human patients with visceral leishmaniasis with combined peptides. Detection of
anti-leishmania total IgG antibodies with synthetic peptides by ELISA assay using sera from patients with active visceral leishmaniasis (n=28) and
healthy individuals with previous negative results in ELISA to Leishmania (n=16) and 2 mg/per well from each peptide. Peptides were combined in
pairs in the same reaction as following: peptides 13 and 19 (panel A), 18 and 19 (panel B), 47 and 13 (panel C), 47 and 17 (panel D) and 47 and 19
(panel E).
doi:10.1371/journal.pntd.0001622.g005
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major factors that hinder control strategies. On the other hand,
highly sensitive diagnosis may require combined antigens. As
indicated by immunoproteomic approaches, Leishmania parasites
display extensive variability in antigenic composition, and
apparently absence of immunodominant antigens when individual
sera samples are analyzed [26], suggesting that single antigen
diagnostic tests may display decreased sensitivities. Indeed, rK39
based tests may lack sensitivity for canine sera with low antibody
concentration [19].
By combining two peptides, increased sensitivities (90–95%) and
specificity (100%) were observed for dog sera with low IFAT
antibodies titers. Similar findings were also observed for sera with
intermediated antibodies titers (80–95% of sensitivity and 100%
specificity). Improved sensitivities may have resulted from
increased number of reactive epitopes, leading to increased OD
readings and numbers of positive sera as compared to the
reactivity with a single peptide. These findings will be particularly
useful for diagnosis of dogs with low and intermediate titers of
antibodies, since most current tests fail in this task.
Since early and sensitive diagnosis is seen as a critical aspect for
management and, possibly, eradication of human visceral leish-
maniasis [12,27–29], we have also investigated the reactivity of the
peptides with sera of patients with active VL. Similarly, improved
results have been observed when the combinations of peptides
were tested against sera of human patients with active disease,
suggesting that the epitopes selected were also recognized
individually by human sera and that their serological reactivity
may be independent and complementary, leading to an additive
effect. Therefore, the association of peptides is an alternative to
broaden the epitopes to be detected by antibodies, improving
sensitivity. On the other hand, the absence of improved sensitivity
for association between the peptides 17 and 47 may be explained
by the presence of low levels of Leishmania specific antibodies in the
control negative sera, since healthy controls were selected from
endemic area and previous exposure of these individuals to
parasite antigens may not be completely ruled out.
In many endemic areas, VL frequently overlaps with the
occurrence of other forms of leishmaniasis or even with other
infectious diseases, such as tuberculosis and leprosy. Cross-
reactivity with antibodies raised against other infectious diseases
consists in an additional shortcoming for development of specific
visceral leishmaniasis diagnosis. Cross-reactivity of synthetic
peptides with sera of patients presenting other infections was
not assessed in the present work. Therefore, additional investi-
gations are further warranted to better determine peptides
specificity.
In conclusion, the combination of synthetic peptides, identified
through B cell epitope predicition, may be useful for the
development of highly sensitive and specific serodiagnosis for
VL. The peptides identified may be especially interesting for the
development sensitive immunochromatographic tests. Since these
test format do not require sophisticated laboratory facilities or
trained personnel staff to be routinely performed, and antibody
quantification is not required for diagnosis of VL, they are more
practical and easily applied, allowing rapid diagnosis in field
conditions in endemic areas of difficult access to laboratory
facilities [11,12,30–32]. Therefore, these peptides coupled to
immunochromatographic tests may allow sensitive and early
detection of infected dogs and their fast withdraw from transmis-
sion areas, regardless their antibody levels and clinical status,
improving the control of VL in endemic areas.
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